MARKET

BNXTF

BNXTF

BioNxt Solutions Inc
OTCMQB
0.461
NaN%
Closed 09:30 02/12 EST
OPEN
--
PREV CLOSE
0.461
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.340
52 WEEK LOW
0.198
MARKET CAP
56.43M
P/E (TTM)
-12.0287
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at BNXTF last week (0202-0206)?
Weekly Report · 3d ago
BioNxt Solutions sichert exklusive Rechte an innovativer Chaperon-Technologie für orale Thin-Film-Drug-Delivery
Reuters · 02/05 08:05
BioNxt Secures Exclusive Rights to Chaperone Drug Delivery Technology
Reuters · 02/05 08:05
Weekly Report: what happened at BNXTF last week (0126-0130)?
Weekly Report · 02/02 09:04
Weekly Report: what happened at BNXTF last week (0119-0123)?
Weekly Report · 01/26 09:04
BioNxt Solutions Advances Cladribine Oral Thin Film for Multiple Sclerosis to First Human Clinical Study
Reuters · 01/26 08:05
BioNxt Moves to Retire $2.7 Million in Debenture Debt via Share Issuance
TipRanks · 01/23 22:39
BioNxt’s Sublingual Cladribine Film Delivers 40% Higher Exposure in Preclinical MS Study
TipRanks · 01/21 15:08
More
About BNXTF
BioNxt Solutions Inc. is a Canada-based bioscience company. The Company focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).

Webull offers BioNxt Solutions Inc stock information, including OTCMQB: BNXTF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNXTF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BNXTF stock methods without spending real money on the virtual paper trading platform.